Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy

[1] Goldhirsch A(2013)Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 24 2206-2223

[2] Winer EP(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-32

[3] Coates AS(2013)Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 2278-2284

[4] Gelber RD(2005)Sensitivity to preoperative chemotherapy varies between breast cancer subtypes Nat Clin Pract Oncol 2 600-600

[5] Piccart-Gebhart M(2015)Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases Br J Cancer 112 345-351

[6] Thürlimann B(2013)Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial Ann Oncol 24 2786-2793

[7] Gianni L(2014)Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer BMC Cancer 14 550-103

[8] Pienkowski T(2011)The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis Br J Cancer 105 93-2966

[9] Im YH(2014)Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 J Clin Oncol 32 2959-193.e187

[10] Roman L(2018)Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images Cell Rep 23 181-2121

[1] Goldhirsch A(2013)Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 24 2206-2223

[2] Winer EP(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-32

[3] Coates AS(2013)Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) Ann Oncol 24 2278-2284

[4] Gelber RD(2005)Sensitivity to preoperative chemotherapy varies between breast cancer subtypes Nat Clin Pract Oncol 2 600-600

[5] Piccart-Gebhart M(2015)Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases Br J Cancer 112 345-351

[6] Thürlimann B(2013)Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial Ann Oncol 24 2786-2793

[7] Gianni L(2014)Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer BMC Cancer 14 550-103

[8] Pienkowski T(2011)The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis Br J Cancer 105 93-2966

[9] Im YH(2014)Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199 J Clin Oncol 32 2959-193.e187

[10] Roman L(2018)Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images Cell Rep 23 181-2121